- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02505139
The Value of Diagnosis and Outcome Prediction in CTC for Metastatic NPC Patients
August 25, 2016 updated by: Ming-Yuan Chen, Sun Yat-sen University
Using Circulating Tumor Cells to Diagnose and Predict Prognosis in Metastatic Nasopharyngeal Carcinoma Patients
A circulating tumor cell (CTC) count is an established prognostic factor in some malignancies such as metastatic breast cancer.
However, the value of CTC in diagnosis and outcome prediction of metastatic nasopharyngeal carcinoma (mNPC) patients is not unknown.
Through the observational prospective clinical trial, sensitivity, specificity, positive and negative predictive values of CTC in diagnosis of mNPC patients will be gained.
Further, the value of CTC in outcome prediction of mNPC patients will be uncovered.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
166
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
NPC patients with distant metastasis
Description
Inclusion Criteria:
- Histologically or radiologically confirmed nasopharyngeal non-keratinizing carcinoma (WHO II, III).
- NPC patients with distant metastasis including synchronous distant metastasis at diagnosis and metachronous distant metastasis after radical treatment.
- A Karnofsky performance status score more than 70.
- The participants provided written informed consent.
Exclusion Criteria:
- A history of previous or synchronous malignant tumors.
- Suffering from severe mental illness synchronously.
- Suffering from severe heart or lung diseases.
- Obvious abnormality in liver and renal function.
- Women in pregnancy or breastfeeding.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Study Group
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall survival rate
Time Frame: 3 years
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of positives that are correctly identified as such
Time Frame: 3 years
|
number of true positives divided by (number of true positives plus number of false negatives)
|
3 years
|
The proportion of negatives that are correctly identified as such
Time Frame: 3 years
|
number of true negatives divided by (number of true negatives plus number of false positives)
|
3 years
|
The proportions of positive results in statistics and diagnostic tests that are true positive results.
Time Frame: 3 years
|
number of true positives divided by number of positive calls
|
3 years
|
The proportions of negative results in statistics and diagnostic tests that are true negative results.
Time Frame: 3 years
|
number of true negatives divided by number of negative calls
|
3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, Tejwani S, Schott AF, O'Rourke MA, Lew DL, Doyle GV, Gralow JR, Livingston RB, Hayes DF. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol. 2014 Nov 1;32(31):3483-9. doi: 10.1200/JCO.2014.56.2561. Epub 2014 Jun 2.
- Zhang Z, Shiratsuchi H, Lin J, Chen G, Reddy RM, Azizi E, Fouladdel S, Chang AC, Lin L, Jiang H, Waghray M, Luker G, Simeone DM, Wicha MS, Beer DG, Ramnath N, Nagrath S. Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model. Oncotarget. 2014 Dec 15;5(23):12383-97. doi: 10.18632/oncotarget.2592.
- Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, Fritsche HA, Hortobagyi GN, Terstappen LW. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol. 2005 Mar 1;23(7):1420-30. doi: 10.1200/JCO.2005.08.140. Erratum In: J Clin Oncol. 2005 Jul 20;23(21):4808.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2014
Primary Completion (Actual)
July 1, 2016
Study Completion (Actual)
August 1, 2016
Study Registration Dates
First Submitted
July 20, 2015
First Submitted That Met QC Criteria
July 21, 2015
First Posted (Estimate)
July 22, 2015
Study Record Updates
Last Update Posted (Estimate)
August 29, 2016
Last Update Submitted That Met QC Criteria
August 25, 2016
Last Verified
August 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Pharyngeal Neoplasms
- Otorhinolaryngologic Neoplasms
- Head and Neck Neoplasms
- Nasopharyngeal Diseases
- Pharyngeal Diseases
- Stomatognathic Diseases
- Otorhinolaryngologic Diseases
- Nasopharyngeal Carcinoma
- Nasopharyngeal Neoplasms
Other Study ID Numbers
- SYSUCCCTC
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nasopharyngeal Neoplasms
-
National Cancer Institute (NCI)NRG OncologyTerminatedRecurrent Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Carcinoma AJCC v8 | Metastatic Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma | Metastatic Nasopharyngeal Nonkeratinizing Carcinoma | Metastatic Nasopharyngeal Undifferentiated Carcinoma | Nasopharyngeal... and other conditionsUnited States, Canada, China, Singapore
-
Cancer Institute and Hospital, Chinese Academy...RecruitingMetastatic Nasopharyngeal CancerChina
-
National Cancer Centre, SingaporeNovartis; Advanced Accelerator ApplicationsRecruitingMetastatic Nasopharyngeal CancerSingapore
-
Groupe Oncologie Radiotherapie Tete et CouTerminatedNasopharyngeal CancersFrance, Tunisia, Morocco, Romania
-
National Cancer Institute (NCI)CompletedRecurrent Nasopharynx Carcinoma | Stage III Nasopharyngeal Carcinoma AJCC v7 | Stage IV Nasopharyngeal Carcinoma AJCC v7 | Stage IVA Nasopharyngeal Carcinoma AJCC v7 | Stage IVB Nasopharyngeal Carcinoma AJCC v7 | Stage IVC Nasopharyngeal Carcinoma AJCC v7 | Nasopharyngeal Nonkeratinizing CarcinomaUnited States, Singapore, China
-
Alliance for Clinical Trials in OncologyNot yet recruitingRecurrent Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Carcinoma AJCC v8 | Metastatic Nasopharyngeal Carcinoma
-
Fuda Cancer Hospital, GuangzhouShenzhen Hank Bioengineering InstituteCompletedMetastatic Nasopharyngeal CancerChina
-
Royal Marsden NHS Foundation TrustCompletedNasopharyngeal Cancers | Intensity Modulated Radiotherapy With ChemotherapyUnited Kingdom
-
National Cancer Institute (NCI)Not yet recruitingStage IV Nasopharyngeal Carcinoma AJCC v8 | Stage II Nasopharyngeal Carcinoma AJCC v8 | Stage III Nasopharyngeal Carcinoma AJCC v8
-
National Cancer Institute (NCI)CompletedRecurrent Nasopharyngeal Cancer | Stage IV Nasopharyngeal CancerUnited States
Clinical Trials on the number of circulating tumor cells
-
Centre Hospitalier Universitaire de NīmesActive, not recruitingAdenocarcinoma of the ProstateFrance
-
Zhujiang HospitalNot yet recruitingRecurrence | Hepatocellular Carcinoma | Surgery | Circulating Tumor CellChina
-
Institut de Cancérologie de LorraineCompleted
-
Beijing Viroad Biotechnology Co., Ltd.UnknownCirculating Tumor Cells.BreastChina
-
Menarini Silicon Biosystems, INCMedex15RecruitingMetastatic Breast CancerUnited States
-
Beijing 302 HospitalRecruiting
-
AC Camargo Cancer CenterInternational Atomic Energy AgencyCompletedBreast Cancer | Brain CancerBrazil
-
Beijing 302 HospitalRecruiting
-
Centre Henri BecquerelNot yet recruitingDiffuse Large B Cell LymphomaFrance
-
Anhui Medical UniversityTechnion, Israel Institute of TechnologyUnknownBreast Cancer | Gastric Cancer | Diagnoses Disease | Circulating Tumor Cell | Volatile Organic Chemicals